News

The company, which has administered the first doses in healthy human volunteers, is also planning to initiate a phase 2/3 study this October. The phase I clinical trial

“We are pleased to have treated the first patient in our Phase 1 trial of RP-L301, marking an important step forward in addressing a high unmet need for

The deal gives Roche exclusive rights for the co-development and commercialisation of pralsetinib outside the US with the exclusion of Mainland China, Hong Kong, Macau, and Taiwan. In

Further, Glenmark has announced a price reduction of 27% for FabiFlu®. The new MRP is INR 75 per tab from the earlier INR 103 per tab. The price

The two of the firms’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme, including BNT162b1 and BNT162b2, are being developed to treat SARS-CoV-2. BioNTech chief medical

“With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including cell and gene therapies

The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology

The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales

More than 20 biopharmaceutical companies have collaborated to establish the AMR Action Fund, which will help focus on medicines that address most resistant bacteria and life-threatening infections. The